701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection

por Garey, Kevin W, Begum, Khurshida, Hu, Chenlin, Wang, Weiqun, Lancaster, Chris, Gonzales-Luna, Anne J, Loveall, Caroline, Jahangir Alam, M, Silverman, Michael
Publicado 2021

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection

por McPherson, Jacob, Hu, Chenlin, Begum, Khurshida, Wang, Weiqun, Lancaster, Chris, Gonzales-Luna, Anne J., Loveall, Caroline, Silverman, Michael H., Alam, M. Jahangir, Garey, Kevin W.
Publicado 2022

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial( )

por Garey, Kevin W, McPherson, Jacob, Dinh, An Q, Hu, Chenlin, Jo, Jinhee, Wang, Weiqun, Lancaster, Chris K, Gonzales-Luna, Anne J, Loveall, Caroline, Begum, Khurshida, Jahangir Alam, M, Silverman, Michael H, Hanson, Blake M
Publicado 2022